Influenza B Virus Hemagglutinin vs Ipilimumab
Influenza B Virus Hemagglutinin vs Ipilimumab: Overview
This comparison examines the pharmacological differences between Influenza B Virus Hemagglutinin and Ipilimumab.
Mechanism of Action
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Ipilimumab β 14.7 days.
Chemical Properties
Type: Influenza B Virus Hemagglutinin β Vaccine component; Ipilimumab β Antibody.